our believe high continued physicians medication. second a you, expect quarter, of prescribing a second treat the more early substantial endocrinologist saw increasingly Korlym number from of patients business with number who our Korlym with growth in an quarterly receive are benefiting is continue. considerably increase have to the identify provide yet our return the to Thank panic record likely are The hypercortisolism, more in physicians treatment will and belief CATALYST for assumed. whose results new The in to our than equally bolster likely we to revenue, it. goes receiving further reflect to that the treatment patients syndrome, Korlym patients to of is ongoing patients group undiagnosed. to eligible disease translation and patients begin investment many evidence In Syndrome patients currently the Results Cushing’s on commercial Cushing's a excellent was Leading strong in hypercortisolism. Charlie. provide with large this once quarter physicians for of stimulate there our of better there business we of study effective to and believed a treatment recognize
and have XXXX Since our of development potential to efforts the the to business powerful are serious million again, growth a excited revenue inception, of therapeutic range our mechanism We hypothesis also modulation can many Cushing's the confident development research our on $XXX guidance be and our this by very in potential $XXX built are disorders. time programs. clinical Syndrome in raising We're cortisol that million.
proprietary products don't approved Our glucocorticoid Korlym’s, cause are cortisol serious of when off-target levels effects which some and progesterone cortisol effects. the to do binding The our modulate or bind and not GR. compounds the to by activated is receptor, receptor receptor the They high.
Interestingly, progesterone while compounds cortisol our activity, modulating they not are without identical. modulate activity,
do brain not. Some barrier others the cross blood
solid perform metabolic potent Others Some of more models tumors. are disease. in best of in models
and conducting prostate specific, appear These our and more proprietary and wide ovarian, programs cortisol NASH global with effects. ALS, Some modulators, tissue a Cushing’s cancer, of study others in diverse of adrenal Currently, variety us to miricorilant, syndrome. relacorilant, disorders. have we course, selected three be qualities dazucorilant to allow are of
and and relacorilant NDA DAZALS patients We studies, from we development. with GRADIENT Phase syndrome, data have trial CATALYST ROSELLA completion GRACE, In next initiation of and months relacorilant expect of in an of additional of NASH. in compounds of our in Cushing’s XX enrollment submission for and Xb the preclinical studies clinical our
time exciting for very a is Corcept. This
hypercortisolism and patients as experienced Korlym leading improvements Patients of drug bleeding, in were no effects induced and There X different in Like effects, of not Cushing's well instances GRADIENT. does a XX% also its variety Phase in efficacy evaluating short, pregnancy, vaginal not GRACE Phase hypertension cortisol symptoms including compelling. potassium, Relacorilant treatment Syndrome. it with low side X are meaningful and is modulator. selective safety cause by not a achieves for competing glucose does a progesterone glucocorticoid related relacorilant in endometrial mechanism Korlym does of relacorilant We trial. or Relacorilant’s as a by does unlike, cortisol effect signs patients by of of side control, induced were experience hypokalemia. for trials, relacorilant and data to at it other and termination PR of Korlym receptor induced is two the of hypokalemia the bind not it discontinuation. thickening pivotal so hypokalemia, of PR the receptor bleeding, vaginal serious and Korlym’s and Korlym, endometrial cause thickening no cause
finishing treatment The trial we Relacorilant trial eager we in available. we a and which With enrollment of promise to to our it NDA, syndrome. tremendous make July of results in in preparing endogenous were published in XXXX. has Frontiers as complete, with focused submit the quarter etiologies in all on GRACE for are plan are Endocrinology second And patients the XXXX. Cushing's
a Patients Our their etiology often of adrenal patients premature adrenal of risk is studying adenoma GRADIENT experience trial in death. this Cushing's health hypercortisolism second an to Phase X decline, less hyperplasia. Syndrome or including is higher whose but by syndrome relacorilant rapid are with caused poor, of outcomes Cushing’s effects
of hypercortisolism that produce data we GRADIENT, prevalence undiagnosed from many depend that X of to CATALYST syndrome CATALYST trial valuable and the frequently is typical announce control While schedule. NDA the and an hypercortisolism Phae study pleased ahead to patient untreated. patients examining is etiology with type about our to we not I'm in Cushing's study diabetes. X,XXX our of do progressing data Cushing's whose X a do goes expect Syndrome on affects expect to patients
blind substantially be of study over randomized, Korlym, is prominent patients The last the independent of will us hypercortisolism with with enter which a controlled largest general United time. studies the design diagnosed choose the in to study in participating years placebo study, in are XX Patients prevalence its the population. diabetologist in type most found higher CATALYST, of help than X we conducted States the and in CATALYST hypercortisolism have many that a double diabetes
positive previous leading this complete received and to the a fourth have study, quarter endocrinologist from estimate. We enrollment in bit our of feedback very regarding expect ahead
is And selective University to induce meant cortisol by other the anti-apoptotic apoptosis. our addition platinum enhance effect. of the control researchers. first is suppressing confirmed study. and many the relacorilant by tumors. by One chemotherapy, increasing women effects program to chemotherapy benefit mechanism mechanisms effect modulator chemotherapy solid three Relacorilant oncology later cortisol’s likely resistant our in women of provided X our cancer. trial meaningful anti-cancer of prominent of ovarian with apoptosis, against at in works blunting is Chicago of Our successful The that beneficial the in investigators postulated by program death Cortisol testing cell the Phase
therapies the and intermittent statistically than survival lines previous While with nab-paclitaxel receive response the also to the who the these arm p-value of intermittently nab-paclitaxel women, effects free compared more the received Taxanes, exhibit relacorilant on received women's significance. the does day a who to in in those progressed including monotherapy. duration and longer to disease of improvement approach comparator they the previous chemo progression day to to relacorilant a significant group live group treatment, beneficial and appear Women some that before have day statistical re-sensitize of after disease relacorilant
versus relacorilant the indicates two who were Our intermittent after years alone. XX% took start date patients XX% only who analysis to the of nab-paclitaxel study alive took
group. been American was XXXX Society and patients. side results to burden the in at Phase Just also trial and Oncology, with to ovarian women study experienced presentations have XXXX this Phase tracks compared progression those plus closely endpoint. women pivotal receive ROSELLA for X Plan of one as who Oncology, resistant XXX secondary primary of recently enrollments Clinical confirmatory Society platinum relacorilant or results our study overall featured who Meeting. a Medical at a alone. in Annual positive survival receive from podium survival receive enrolling in and is were alone. ESMO ROSELLA, plus the nab-paclitaxel X prestigious its to ASCO goal no Journal a Results Oncology. Clinical Phase designed The endpoint meeting published is one to XXXX X replicate key effect important, the simply nab-paclitaxel European cancer a randomized nab-paclitaxel the larger The of the relacorilant additional free nab-paclitaxel in
clinicians the the in leading with collaboration in States of Network from study Group this in gynecological conducting European Oncology United Trials group oncology and Gynecological are the We Europe.
enrollment to side with women in increased platinum important plus have their to free overall without oncologists track complete survival by on benefit, potential the the the Leading year. and would advance potential relacorilant of in become ovarian of progression has resistant are a end medical nab-paclitaxel care effect told improved standard and that relacorilant’s an us gynecological that burden We constitute view, new cancer.
which by deprived androgen mechanism Enzalutamide is modulation why eventually tumor stimulation is prostate pathway. resurgent experienced antagonist treated disease, cancer to growth growth. Second to activity receptor cortisol of cortisol improve major an by widely Cortisol with useful a stimulation, with important tumor stimulate androgen their switched reason blocking prescribed patients a
therapy adding deprivation route. tumor Our androgen cortisol hypothesis and to is close a this that modulator escape
Our before an these patients collaborators begin randomized controlled at Enzalutamide plan quarter. relacorilant of placebo with this trial plus a have to Chicago had of prostatectomy the cancer in X initial patients University Phase prostate
response. to Third therapeutic immune system. therapies enhancing the immune the intended tumors cancer immune system, to effectiveness Cortisol blunt of the which mechanism may by suppresses seeks the treat stimulate body's
these checkpoint therapies. modulator of that is the a hypothesis as enhance immunotherapies to such Our inhibitors adding effectiveness cortisol may
randomized dazucorilant and placebo relacorilant patients. better in cancer. tumors inflammation briskly produce modulator dazucorilant Disease and form for are a ALS, Gehrig's need is selective treating pembrolizumab a advanced atrophy. shown Lou is Xb XXX adrenal X patient , the pembrolizumab reducing ALS treatment. as trial cancer, rarely is urgent in as double in models patients cortisol our a animal controlled improving known neural Phase these that adrenal with is has PDX effective an DAZALS muscular ALS of of cortisol. blind promise We this great of of trial in performance enrolling with devastating excess motor conducting checkpoint with commonly Phase illness patients monotherapy plus inhibitor
and this year. a TRICALS, track academic in with in by are recently collaboration in on early Europe. right enrollment are We added ALS clinical DAZALS States, study next complete consortium We important conducting to United trials in leading the
we as NASH, the liver demonstrate Miricorilant our a ALP in and period patients Finally, albeit continues I'll disorder rarely is patients promise afflicts than a XXX seen NASH substantial In more occurred reductions patients milligrams much to of in the liver expected, but prior fat millions an that for also The and over improvements daily exhibited these serious medication studies, greater NASH. of large liver United our ASD. oral rapidly rapid to milligrams States. program who liver XXX in transient of fat, in enzymes, of received treatment. treatment had elevations and miricorilant great or was turn in any
approximately in Our timing study, liver disease. Homa and showed experience miricorilant of evaluated receive fat schedules and such ongoing dosing liver orally range weeks of key patients week experienced These Phase an Xb enzymes which who to improvements markers XX% liver measures and patients LDL. just a metabolic XXX doses reduction dose in in also triglycerides, milligrams as XX lipid found a and of miricorilant improvements for that IR, serum twice of
Phase Xb these at Importantly, results in miricorilant for scientific presentation and fourth a will conference the to was plan very quarter. initiate trial a well tolerated. submit We
about has invest optimistic Corcept, and even substantial as development advancing potential R&D in the of growth generates extremely are Syndrome we conclusion, tremendous Cushing’s future programs. we business our profits In
We this revenue are to guidance and anticipate for raising year our again for years come. growth
is study undiagnosed. by as and whose Syndrome CATALYST patients control difficult treatment promise, Our of the goes diabetes hypercortisolism, to caused with will the population improve great a physicians help frequently screening to Cushing’ holds generated data
hypercortisolism hypercortisolism. patients, disease their is and are their a of diabetes these For symptom
benefits other treat offer Our and effective diseases. Cushing's with development programs cortisol potential modulation the disorders. the range validates patients serious are long is and a can our Reducing to a and belief to generating activity straightforward increasing cortisol way of has evidence treat Syndrome substantial wide to held
current there will but are others. NASH examples, be and ALS cancer, Ovarian
modulators different data GRACE, In addition and see cortisol very GRADIENT we dazucorilant Syndrome. our proprietary and studies with the have CATALYST potentially to from In many selective relacorilant, in XX next attributes. miricorilant, portfolio our in we other clinical will Cushing’s months,
controlled relacorilant resistant We large Cushing’s we'll NDA studies in ovarian enrollment and of cancer Syndrome, platinum and will ALS. submit complete and
IIb Phase in patients a begin study with also will We NASH.
investors is possible. creative for employees that dedicated this said, and time for Corcept. for I As here I'll stop exciting loyal an our thank I making questions.
